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Tenofovir (TFV) is eliminated by renal excretion, which is mediated throughmultidrug-resistant protein 2 (MRP2) andMRP4,
encoded by ABCC2 and ABCC4, respectively. Genetic polymorphisms of these transporters may affect the plasma concentrations
of tenofovir. Therefore, the aim of this study was to investigate the influence of genetic and nongenetic factors on tenofovir
plasma concentrations. A cross-sectional study was performed in Thai HIV-infected patients aged >18 years who had been re-
ceiving tenofovir disoproxil fumarate at 300 mg once daily for at least 6 months. Amiddose tenofovir plasma concentration was
obtained. Multivariate analysis was performed to investigate whether there was an association between tenofovir plasma concen-
trations and demographic data, including age, sex, body weight, estimated glomerular filtration rate (eGFR), hepatitis B virus
coinfection, hepatitis C virus coinfection, duration of tenofovir treatment, concomitant use of ritonavir-boosted protease inhibi-
tors, and polymorphisms of ABCC2 and ABCC4. A total of 150 Thai HIV-infected patients were included. The mean age of the
patients was 43.9 7.2 years. The mean tenofovir plasma concentration was 100.3 52.7 ng/ml. In multivariate analysis, a low
body weight, a low eGFR, the concomitant use of ritonavir-boosted protease inhibitors, and the ABCC4 4131T ¡ G variation
(genotype TG or GG) were independently associated with higher tenofovir plasma concentrations. After adjusting for weight,
eGFR, and the concomitant use of ritonavir-boosted protease inhibitors, a 30% increase in the mean tenofovir plasma concen-
tration was observed in patients having the ABCC4 4131 TG or GG genotype. Both genetic and nongenetic factors affect tenofo-
vir plasma concentrations. These factors should be considered when adjusting tenofovir dosage regimens to ensure the efficacy
and safety of a drug. (This study has been registered at ClinicalTrials.gov under registration no. NCT01138241.)
Tenofovir disoproxil fumarate (TDF), an oral prodrug of teno-fovir (TFV), is widely used for the treatment of human immu-
nodeficiency virus (HIV) infection because of its high potency,
good safety profile, limited drug interaction, and convenient
once-daily dosing (1, 2). After absorption, TDF is rapidly con-
verted to tenofovir. Tenofovir is then phosphorylated intracellu-
larly to tenofovir diphosphate, an active analog, which inhibits
HIV reverse transcriptase, resulting in a termination DNA chain
elongation (1, 2).
Tenofovir is eliminated by renal excretion through glomerular
filtration and active tubular secretion. It is transported into kidney
tubular cells by organic anion transporter 1 (OAT1) and OAT3,
encoded by the SLC22A6 and SLC22A8 genes, respectively, at the
basolateral membrane. Subsequently, tenofovir is secreted to
the tubular lumen by multidrug-resistant protein 2 (MRP2) and
MRP4, encoded by the ABCC2 and ABCC4 genes, respectively, at
the apical membrane (3). Therefore, genetic polymorphisms of
these transporter genes may affect the transport of tenofovir at
kidney tubular cells and may have an impact on tenofovir plasma
concentrations.
Previous studies have shown that the polymorphisms of
ABCC2 and ABCC4 are associated with higher tenofovir concen-
trations (4, 5) and a higher tenofovir plasma concentration is as-
sociated with renal impairment (6, 7). The cutoff values of the
middose (12-h) tenofovir concentration (C12) and the trough
(minimum) concentration (Cmin) (160 ng/ml and 90 ng/ml,
respectively) were proposed to discriminate a risk of kidney tubu-
lar dysfunction (KTD) (6, 7). These results suggest that genetic
variation in tenofovir transporter genes may lead to overexposure
to tenofovir, resulting in kidney tubular cell damage. Therefore, a
study investigating the influence of genetic and nongenetic factors
on tenofovir concentrations is crucial for the optimization of dos-
age regimens to prevent renal toxicity.
However, there are limited studies showing an association be-
tween genetic polymorphisms of drug transporters and tenofovir
plasma concentrations. Therefore, the aim of this study was to
investigate the influence of genetic variants ofABCC2 andABCC4
and nongenetic factors on tenofovir plasma concentrations. The
results of this studywill be useful for the design of tenofovir dosage
regimens to optimize drug concentrations and ensure the safety
and efficacy of this drug.
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MATERIALS AND METHODS
Study population. A cross-sectional study was performed in Thai HIV-
infected patients recruited from the HIV Netherlands Australia Thailand
Research Collaboration (HIV-NAT), Bangkok, Thailand, from March
2012 to May 2013 (ClinicalTrials.gov registration no. NCT01138241).
Patients aged 18 years and older who had been receiving TDF at 300 mg
once daily for at least 6 months for the treatment of HIV infection were
included in the study. Blood samples were obtained at middose (10 to 14
h after the last dose) for tenofovir concentration determination and geno-
typing assay. Demographic and laboratory data, including age, sex, body
weight, serum creatinine concentration, hepatitis B virus coinfection,
hepatitis C virus coinfection, duration of tenofovir treatment, and con-
comitant use of antiretroviral drugs, were recorded. The estimated glo-
merular filtration rate (eGFR) was calculated using the modification of
diet in renal disease (MDRD) formula. The study was approved by the
Institutional Review Board of the Faculty of Medicine, Chulalongkorn
University, Bangkok, Thailand. All patients provided written informed
consent.
Determination of tenofovir plasma concentration. Tenofovir
plasma concentrations were determined at the HIV-NAT research labo-
ratory by a validated high-performance liquid chromatography assaywith
a fluorescence detector using themodifiedmethod ofDroste et al. (8)with
a lower limit of quantification of 15 ng/ml. The tenofovir calibration curve
was linear over the concentration range of from 15 to 1,500 ng/ml. The
within-run and between-run coefficients of variation (precision)were less
than 10%, and the accuracy of the tenofovir concentrationwas between 95
and 105%.
Genotyping assay.Human genomicDNAwas extracted from periph-
eral blood mononuclear cells by use of a QIAamp DNA blood minikit
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol.
Five single nucleotide polymorphisms, ABCC2 24C ¡ T (rs717620),
ABCC2 1249G ¡ A (rs2273697), ABCC2 3972C ¡ T (rs3740066),
ABCC4 3463A ¡ G (rs1751034), and ABCC4 4131T ¡ G (rs3742106),
were genotyped. These polymorphisms were chosen on the basis of the
allele frequency, evidence of their association with tenofovir plasma con-
centrations or toxicity, and their influence on drugs excreted via glomer-
ular filtration and active tubular secretion (4, 9–12).
The genotyping assay was performed by real-time PCR using a Taq-
Man allelic discrimination assay with a predesigned probe and primer
(Applied Biosystems, CA, USA). The PCR conditions were as follows:
95°C for 10 min, followed by 92°C for 15 s and 60°C for 1 min.
Statistical analyses. Statistical analyses in this study were performed
using Statistical Package for the Social Sciences (SPSS; version 17; SPSS
Co., Ltd., Bangkok, Thailand) software. The demographic characteristics
of the patients are presented as the mean  standard deviation (SD) for
continuous data and the frequency (number and percentage of patients)
for categorical data. The allele frequencies of ABCC2 and ABCC4 were
calculated. The distribution of the observed genotype according toHardy-
Weinberg equilibrium was tested by the chi-square test. Due to the small
number of patients in some genotype groups, the mean tenofovir plasma
concentration was compared between 2 genotype groups, patients with a
homozygous wild-type allele and patients with at least 1 variant allele, by
Student’s t test. A regression model was used to assess whether an associ-
ation exists between tenofovir plasma concentrations and demographic
data, including age, sex, body weight, eGFR, hepatitis B virus coinfection,
hepatitis C virus coinfection, duration of tenofovir treatment, polymor-
phisms of ABCC2, polymorphisms of ABCC4, and concomitant use of
ritonavir-boosted protease inhibitors. Any independent variables with a P
value of 0.1 in the univariate analysis were entered into a model of
multivariable regression analysis using the stepwise method. A P value of
0.05 was considered statistically significant.
RESULTS
Demographic data. A total of 150 patients providing 150 blood
samples were included in this study. A summary of the patient
characteristics is presented in Table 1. Among the 150 patients,
101 (67.3%), 48 (32.0%), and 1 (0.7%) patients were receiving
tenofovir in combination with nonnucleoside reverse transcrip-
tase inhibitors (NNRTIs), ritonavir boosted-protease inhibitors,
and an integrase inhibitor, respectively.
The frequencies of genetic polymorphisms of ABCC2 and
ABCC4 are shown in Table 2. All polymorphisms were in Hardy-
Weinberg equilibrium (2, P 0.05).
Predictors of tenofovir plasma concentrations. The mean
tenofovir plasma concentration for each polymorphism is pre-
sented in Table 3. Tenofovir plasma concentrations between pa-
tientswith a homozygouswild-type allele and patientswith at least
1 variant allele were not significantly different for all genetic poly-
morphisms.
The influence of genetic and nongenetic factors on tenofovir
plasma concentrations in univariate and multivariate analyses is
presented in Table 4. Factors including low body weight, low
eGFR, concomitant use of ritonavir-boosted protease inhibitors,
and having anABCC4 4131T¡G variation (genotype TG or GG)
were independently associated with higher tenofovir plasma con-
centration (P  0.05) in the multivariate analysis. Figure 1 pres-
ents the relationship between tenofovir plasma concentrations
and eGFR by ABCC4 4131T ¡ G genotype. Patients having the
ABCC4 4131 TG or GG genotype tended to have higher tenofovir
plasma concentration than those having the TT genotype. On the
basis of the results from multivariate analysis, it was shown that
after controlling for body weight, eGFR, and concomitant use of a
TABLE 1 Demographic characteristics of study patientsa
Characteristic Value
No. (%) of patients of the following sex:
Male 85 (56.7)
Female 65 (43.3)
Mean age SD (yr) 43.9 7.2
Mean body wt SD (kg) 60.3 11.9
Mean body mass index SD (kg/m2) 22.5 3.6
Mean serum creatinine concn SD (mg/dl) 0.9 0.2
Mean eGFRb SD (ml/min/1.73 m2) 90.3 18.0
No. (%) of patients:
Hepatitis B virus antigen positive 60 (40.0)
Hepatitis C antibody positive 12 (8.0)
Mean duration of tenofovir treatment SD (yr) 3.7 2.0
Mean tenofovir sampling time after last dose SD (h) 11.9 0.8
Mean tenofovir plasma concn SD (ng/ml) 100.3 52.7
No. (%) of patients receiving the following comedications:
Lamivudine 94 (62.7)
Emtricitabine 46 (30.7)
Zidovudine 10 (6.7)
Efavirenz 91 (60.7)
Nevirapine 10 (6.7)
Lopinavir-ritonavir 17 (11.3)
Atazanavir-ritonavir 9 (6.0)
Darunavir-ritonavir 3 (2.0)
Saquinavir-ritonavir 19 (12.7)
Raltegravir 1 (0.7)
a Data are for 150 patients.
b Calculated by use of the MDRD formula.
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ritonavir-boosted protease inhibitor, patients having the ABCC4
4131 TG or GG genotype had, on average, 30% highermean teno-
fovir plasma concentrations than patients having theABCC4 4131
TT genotype (P 0.007) (Fig. 2).
DISCUSSION
Although tenofovir is well tolerated, the induction of nephrotox-
icity by tenofovir has been reported (13). There is evidence of an
association between tenofovir plasma concentrations and renal
toxicity (4, 6, 7, 14). A study by Rodríguez-Nóvoa et al. has shown
that patients with a tenofovir plasma concentration of more than
160 ng/ml at middose (10 to 14 h after the last dose) were at a 4.8
times higher risk of experiencing KTD than patients with a teno-
fovir plasma concentration below this cutoff value (6). Moreover,
a previous study by Poizot-Martin et al. suggested that a threshold
tenofovir trough concentration of 90 ng/ml is a predictor of a
risk of KTD (7). Therefore, tenofovir dose adjustment is crucial in
decreasing the risk of renal toxicity when tenofovir is prescribed.
The pharmacokinetics of tenofovir are highly variable between
individuals (4, 15, 16). Thus, identifying factors that contribute to
this high variability would be beneficial for tenofovir dose adjust-
ment. In this study, we investigated the influence of both genetic
and nongenetic factors on tenofovir plasma concentrations. The
results from multivariate analysis showed that tenofovir plasma
concentrations are associated with body weight, eGFR, concomi-
tant use of a ritonavir-boosted protease inhibitor, and the poly-
morphism ABCC4 4131T ¡ G. A lower patient body weight was
associated with higher tenofovir plasma concentrations in our
study. This finding is consistent with the results from previous
studies which demonstrated that body weight is one of the impor-
tant predictors of tenofovir’s pharmacokinetics (4, 15, 17).
Tenofovir ismainly eliminated by renal excretion. It is effluxed
across renal proximal tubule cells by MRP2 and MRP4, encoded
by the ABCC2 and ABCC4 genes, respectively. Genetic polymor-
phisms of these transporters have been reported to be associated
with higher levels of tenofovir exposure and KTD (4, 5, 9, 10, 18).
A study by Kiser et al. found that patients carrying the ABCC4
3463A ¡ G variation had lower tenofovir renal clearance than
those carrying the wild type, leading to an approximately 32%
increase in the tenofovir area under the curve in theABCC4 3463A
¡ G variant group (9). A more recent study in a Thai HIV-in-
fected population reported that theABCC224 CC genotype was
associated with a higher tenofovir plasma concentration than the
CT or TT genotype (114 ng/ml for the CC genotype and 93 ng/ml
for the CT or TT genotype) (4). However, that study investigated
only a limited number of genes (ABCC2 24C ¡ T and ABCB1
3435C ¡ T), and it is possible that the influence of polymor-
phisms of other transporter genes may have not been detected.
Interestingly, we could not confirm the influence of the ABCC4
3463A ¡ G and ABCC224C ¡ T polymorphisms on tenofovir
plasma concentrations in our study. This could be due to the small
number of patients enrolled in previous studies and the different
ethnicities and the different genetic polymorphisms of the pa-
tients investigated among the studies. However, it could be pos-
tulated that several transporter genes may play a role in tenofovir
elimination. The present study is the first to report an association
between the ABCC4 4131T ¡ G variation and tenofovir plasma
concentrations. The results from multivariate analysis showed
that after controlling for bodyweight, eGFR, and concomitant use
of a ritonavir-boosted protease inhibitor, patients carrying the
ABCC4 4131 TG or GG genotype had, on average, a 30% higher
mean tenofovir plasma concentration than patients carrying the
TT genotype. Although an association between the ABCC4 4131T
¡ G polymorphism and the tenofovir plasma concentrations has
never been found, the influence of this polymorphism on the in-
tracellular concentrations of lamivudine has been reported (12). A
study by Anderson et al. found a 20% increase in the intracellular
concentrations of lamivudine in patients carrying the ABCC4
4131 TG or GG genotype than those carrying the TT genotype
(12). A potentialmechanismof this interactionwas proposed. The
ABCC4 4131T ¡ G variation may reduce MRP4 protein expres-
sion and decrease the transportation of drugs in kidney tubular
cells (12).
As the elimination of tenofovir requires drug transporters,
tenofovir may be susceptible to a drug transporter-mediated in-
TABLE 2 Frequencies of ABCC2 and ABCC4 genotype polymorphismsa
Genetic
polymorphism
Genotype Allele
Genotype
No. of
patients
% of
patients Allele
% of
patients
ABCC224C ¡ T CC 98 65.3 C 80.7
CT 46 30.7 T 19.3
TT 6 4.0
ABCC2 1249G ¡ A GG 123 82.0 G 90.7
GA 26 17.3 A 9.3
AA 1 0.7
ABCC2 3972C ¡ T CC 94 62.7 C 78.3
CT 47 31.3 T 21.7
TT 9 6.0
ABCC4 3463A ¡ G AA 96 64.0 A 80.7
AG 50 33.3 G 19.3
GG 4 2.7
ABCC4 4131T ¡ G TT 34 22.7 T 49.3
TG 80 53.3 G 50.7
GG 36 24.0
a Data are for 150 patients.
TABLE 3 Association between tenofovir plasma concentrations and
ABCC2 and ABCC4 genotypes
Genetic
polymorphism Genotype
Mean tenofovir plasma
concn SD (ng/ml)
P
valuea
ABCC224C ¡ T CC 101.5 57.0 0.706
CT or TT 98.1 43.9
ABCC2 1249G ¡ A GG 100.3 55.7 0.984
GA or AA 100.5 37.0
ABCC2 3972C ¡ T CC 102.8 57.1 0.455
CT or TT 96.1 44.6
ABCC4 3463A ¡ G AA 104.7 57.2 0.177
AG or GG 92.6 43.0
ABCC4 4131T ¡ G TT 86.0 30.7 0.072
TG or GG 104.5 57.0
a Determined by Student’s t test.
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teraction (1, 19). Previous reports showed that ritonavir-boosted
protease inhibitors, including lopinavir-ritonavir, atazanavir-
ritonavir, and darunavir-ritonavir, can increase the level of teno-
fovir exposure by approximately 17 to 37% (1, 9, 20). These inter-
actions were confirmed in our study. The concomitant use of a
ritonavir-boosted protease inhibitor resulted in a 35% increase in
the tenofovir plasma concentration. Even though the exact mech-
anism of the interaction between a ritonavir-boosted protease in-
hibitor and tenofovir has not been conclusively defined, possible
mechanisms have been proposed. Ritonavir was shown to be a
potent inhibitor of P glycoprotein (P-gp) andMRP2 (21). Inhibi-
tion of P-gp by a ritonavir-boosted protease inhibitor could lead
to increased absorption in the gut (22). On the other hand, an
increase in the level of tenofovir exposure due to inhibition of
MRP2, an efflux transporter from the renal proximal tubule cells,
resulting in decreased renal excretion, was also speculated (21).
Some study limitations should be noted. First, the polymor-
phisms of other transporter genes involving tenofovir influx
transport, such as SLC22A6 and SLC22A8, were not investigated
in this study. However, there is evidence that genetic polymor-
phisms of these transporters are not associated with the pharma-
cokinetics of several drugs, including tenofovir, adefovir, prava-
TABLE 4 Univariate and multivariate analyses of genetic and nongenetic factors for tenofovir plasma concentrations
Factor
Univariate analysis Multivariate analysisa
B 95% CIb P valuec B 95% CI P valuec
Female 13.986 3.079 to 31.052 0.107
Age 0.183 1.002 to 1.368 0.760
Body wt 0.918 1.622 to0.214 0.011* 0.861 1.494 to0.229 0.008**
eGFRd 0.970 1.420 to0.520 0.001* 0.934 1.375 to0.492 0.001**
Hepatitis B virus positive 12.241 29.541 to 5.059 0.164
Hepatitis C virus positive 0.275 31.721 to 31.171 0.986
Duration of tenofovir treatment 0.385 4.677 to 3.907 0.860
Concomitant RTV-boosted PIe 40.088 22.998 to 57.177 0.001* 29.231 12.649 to 45.813 0.001**
ABCC224 CT or TT 3.435 21.352 to 14.482 0.706
ABCC2 1249 GA or AA 0.217 21.989 to 22.422 0.984
ABCC2 3972 CT or TT 6.675 24.279 to 10.930 0.455
ABCC4 3463 AG or GG 12.127 29.791 to 5.536 0.177
ABCC4 4131 TG or GG 18.464 1.690 to 38.619 0.072* 25.180 7.049 to 43.310 0.007**
a Factors with P values of0.1 in the univariate analysis were entered into the multivariate analysis.
b CI, confidence interval.
c *, P 0.1; **, P 0.05.
d Calculated by use of the MDRD formula.
e RTV, ritonavir; PI, protease inhibitor.
FIG 1 Relationship between tenofovir plasma concentrations and eGFR, calculated by use of theMDRD formula, subgrouped byABCC4 4131 TT genotype and
ABCC4 4131 TG or GG genotype.
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statin, and torsemide (9, 23–25). Therefore, the transportation of
drugs across the apical membrane (from cell to tubular lumen) by
multidrug-resistant proteins may be a rate-limiting step for drug
secretion (23, 25). Thus, it is likely that the polymorphisms of
organic anion transporters may not be associated with tenofovir’s
pharmacokinetics. Furthermore, we studied a selected number of
efflux transporter polymorphisms. A more comprehensive inves-
tigation of various polymorphisms should be performed. Second,
the overall effect of ritonavir-boosted protease inhibitors was
quantified in this study. Due to the small number of patients using
atazanavir-ritonavir and darunavir-ritonavir, the influence of
each ritonavir-boosted protease inhibitor was not identified.
Third, due to the cross-sectional design of the study, an associa-
tion between a higher tenofovir plasma concentration and renal
toxicity cannot be confirmed. However, it is worth mentioning
that if a middose concentration of tenofovir of160 ng/ml were
used as the cutoff for a risk of renal toxicity, all of the patients
having a tenofovir concentration atmiddose of160 ng/ml in our
studywould have theABCC4 4131TGorGGgenotype. Therefore,
it is possible that patients having theABCC4 4131T¡G variation
could be at higher risk of renal toxicity because of a high tenofovir
plasma concentration. Finally, due to the inhibitory effect of
ritonavir-boosted protease inhibitors on the renal tubular secre-
tion of serum creatinine, a rise in the serum creatinine concentra-
tion could be observed in a group of patients using ritonavir-
boosted protease inhibitors. This may lead to an underestimate of
the eGFR in this group of patients. However, with the small in-
crease in the serum creatinine concentration reported in a previ-
ous study (0.08 mg/dl) (26), this would result in a negligible de-
crease in the eGFR and should not affect the results of this study.
In summary, this study showed that both genetic and nonge-
netic factors influence tenofovir plasma concentrations, which
could be associatedwith tenofovir-induced renal toxicity. Patients
who had a low body weight and a low eGFR, who concomitantly
used a ritonavir-boosted protease inhibitor, and who had the
ABCC4 4131 TG or GG genotype were at risk of a higher tenofovir
concentration. Therefore, the tenofovir concentration should be
closely monitored in these groups of patients.
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